Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-189: Pembrolizumab plus Chemotherapy in Metastatic Non-Squamous NSCLC
NCT02578680Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2016
- Primary completion
- Nov 2017
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 3 trial of pembrolizumab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Merck & Co.. Started Jan 2016; status: completed.
02
Drugs
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT02578680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02578680.